Joe Rogan's ibogaine advocacy sparks White House tension

Joe Rogan's advocacy for the psychedelic drug ibogaine has reportedly led to tensions with a key aide in the Trump administration, according to The Atlantic. The conflict arose as Rogan sought to influence policy changes regarding the drug, which is being studied for its potential to treat addiction and trauma.

Rogan's push for ibogaine

The Atlantic reports that in April, Joe Rogan reached out to then-President Donald Trump to discuss ibogaine, a psychedelic derived from a Central African shrub. Rogan, known for his popular podcast, was interested in promoting the drug's therapeutic benefits. Trump reportedly responded positively, suggesting FDA approval could be pursued.

Conflict with Heidi Overton

The situation became complicated when Dr. Heidi Overton, a deputy assistant to the president focusing on health policy, became involved. Overton led efforts to revise a draft executive order on psychedelic therapies, which had been initiated after Rogan's outreach. Her involvement led to friction with Rogan and his allies, who felt Overton was undermining Trump's intentions.

Threats to withdraw from ceremony

According to The Atlantic, the dispute escalated to the point where Rogan and W. Bryan Hubbard, CEO of Americans for Ibogaine, threatened to withdraw from a signing ceremony if they were not included in the final edits of the order. The draft, initially 1,400 words, was reduced to about 900 words by the time it was signed.

Why it matters

This incident highlights the complexities of drug policy reform and the influence of public figures like Rogan in shaping political agendas. It also underscores the challenges faced by policymakers in balancing advocacy with regulatory processes.

White House Press Secretary Karoline Leavitt and Chief of Staff Susie Wiles defended Overton, emphasizing her role in the administration's fast-paced decision-making environment.